The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

Haematologica

Volumn 94, Issue 5, 2009, Pages 729-732

  Zipperer, Esther ^a   Pelz, Daniela ^a   Nachtkamp, Kathrin ^a   Kuendgen, Andrea ^a   Strupp, Corinna ^a   Gattermann, Norbert ^a   Haas, Rainer ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Charlson Comorbidity Index; Comorbidity score; Hematopoietic Stem Cell Transplantation Comorbidity Index; International Prognostic Scoring System; Myelodysplastic syndromes; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; COMORBIDITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; GERMANY; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH ULCER; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 66049093852     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.002063     Document Type: Article

References (11)

1. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000;35:181-200.
2. Feinstein AR. The pretherapeutic classification of comorbidity in chronic disease. J Chron Dis 1970; 23:455-468
3. Sabin SL, Rosenfeld RM, Sundaram K, Har-el G, Lucente FE. The impact of comorbidity and age on survival with laryngeal cancer. Ear Nose Throat J 1999;78:578. (Pubitemid 29404356)
4. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 1997;107:1469-1475
5. Lubke T, Monig SP, Schneider PM, Holscher AH, Bollschweiler E. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? Zentralbl Chir 2003;128:970-976
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383 (Pubitemid 17055592)
7. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251 (Pubitemid 24361532)
8. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106: 2912-2919
9. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25:4246-4254
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088
11. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-59